Processing

Please wait...

Settings

Settings

Goto Application

1. WO2002018382 - PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Publication Number WO/2002/018382
Publication Date 07.03.2002
International Application No. PCT/JP2001/007322
International Filing Date 27.08.2001
Chapter 2 Demand Filed 21.02.2002
IPC
C07D 471/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
CPC
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
08for nausea, cinetosis or vertigo; Antiemetics
A61P 1/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
10Laxatives
A61P 1/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
18for pancreatic disorders, e.g. pancreatic enzymes
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
Applicants
  • FUJISAWA PHARMACEUTICAL CO., LTD. [JP]/[JP] (AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MG, MK, ML, MN, MR, MW, MX, MZ, NE, NL, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW)
  • AKAHANE, Atsushi [JP]/[JP] (UsOnly)
  • TANAKA, Akira [JP]/[JP] (UsOnly)
  • MINAGAWA, Masatoshi [JP]/[JP] (UsOnly)
  • ITANI, Hiromichi [JP]/[JP] (UsOnly)
  • OHTAKE, Hiroaki [JP]/[JP] (UsOnly)
Inventors
  • AKAHANE, Atsushi
  • TANAKA, Akira
  • MINAGAWA, Masatoshi
  • ITANI, Hiromichi
  • OHTAKE, Hiroaki
Agents
  • TABUSHI, Eiji
Priority Data
PQ969828.08.2000AU
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF
(FR) COMPOSE DE PYRAZOLOPYRIDINE ET SON UTILISATION PHARMACEUTIQUE
Abstract
(EN)
A pyrazolopyridine compound of formula (I) wherein: R1 is hydro gen, lower alkyl optionally substituted by susbtituent(s), or cyclo(lower)alkyl which may be interrupted by an oxygen or nitrogen atom and optionally substituted by substituent(s); R2 is hydrogen, halogen or lower alkoxy; R3 is a substituent; and n is an integer from 1 to 4, provided R3 may be different from each other when n is 2, 3 or 4, or a salt thereof. The pyrazolopyridine compound (I) and salt thereof of the present invention are adnosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.) Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like.
(FR)
L'invention concerne un composé de pyrazolopyridine de formule (I) ou un sel dudit composé. Dans cette formule, R1 est hydrogène, alkyle inférieur éventuellement substitué par un ou plusieurs substituants, ou cycloalkyle (inférieur) pouvant être interrompu par un atome d'oxygène ou d'azote et éventuellement substitué par un ou plusieurs substituants; R2 est hydrogène, halogène ou alcoxy inférieur; R3 est un substituant; et n est un entier de 1 à 4, à condition que R3 puisse être différent lorsque n vaut 2, 3 ou 4. Le composé de pyrazolopyridine (I) et le sel dudit composé sont des antagonistes d'adénosine et trouvent une utilité dans la prévention et/ou le traitement de la dépression, de la démence (maladie d'Alzheimer, démence cérébrovasculaire, démence associée à la maladie de Parkinson, etc.), de la maladie de Parkinson, de l'anxiété, de la douleur, d'affections cérébrovasculaires (telles qu'un accident vasculaire cérébral), de l'insuffisance cardiaque, etc.
Latest bibliographic data on file with the International Bureau